Important Safety Information
Prescribing Information
Medication Guide
For Healthcare Professionals
TOUCH Program

Important Safety Information
Prescribing Information
Medication Guide
For Healthcare Professionals

BIOGEN SUPPORT 800.456.2255

About TYSABRI
Starting TYSABRI
What is relapsing MS?
- Learn about RMS
- RMS glossary
Personal stories
- Fighter blog
- Fighter videos
Support & events

SIGN UP
MY ACCOUNT
- My preferences
- Logout
BIOGEN SUPPORT BIOGEN SUPPORT 800.456.2255

Important Safety Information
Prescribing Information
Medication Guide
For Healthcare Professionals
TOUCH Program

Register Today

Benefits of registering:

Stay up to date on the latest news from TYSABRI by receiving our free eNewsletters and updates
Get a free TYSABRI information kit mailed to your home
Find MS events—great opportunities to connect with others in your area living with MS

If you have already registered on TYSABRI.com or any other website from Biogen, sign in here.

Get Started

*Required

*Email address:*

Please tell us a little more about yourself:

*Email address:*

*Create password: (8-15 characters):*

*Confirm Password:*

*First Name:*

*Last Name:*

*Address:*

*Zip code:*

*City:*

*State:

Daytime phone:

**Which of the following describes you best?

Person with MS

MS Care Partner

Other

*When were you diagnosed with relapsing forms of MS?

**Are you currently treating your relapsing forms of MS?

Yes

No

**What are you currently taking to treat your relapsing forms of MS?
--Please see below for Important Safety Information (ISI) and full Prescribing Information (PI) for Biogen products, including Boxed Warning and Medication Guide for TYSBRI® (natalizumab), Medication Guides for AVONEX® (interferon beta-1a) and PLEGRIDY® (peginterferon beta-1a), and Patient Information fot TECFIDERA® (dimethyl fumarate) and VUMERITY™ (diroximel fumarate). The following are trademarks of the respectives companies listed: Aubagio®-Genzyme Corporation; Betaseron®-Bayer; Copaxone®-Teva Pharmaceutical Industries Ltd.; Extavia®-Novartis AG; Gilenya®-Novartis AG; Glatopa®-Novartis AG; Lemtrada®-Genzyme Corporation; Mavenclad®-EMD Serono Inc; Mayzent®-Novartis AG; Novantrone®-EMD Serono Inc; Ocrevus™-Genentech USA, Inc.; Rebif®-EMD Serono, Inc.

*What have you previously taken to treat your relapsing MS? Check all that apply:

Aubagio^® (teriflunomide)

Betaseron^® (interferon beta-1b)

Copaxone^® (glatiramer acetate injection)

Extavia^® (interferon beta-1b)

Gilenya^® (fingolimod)

Glatopa^® (glatiramer acetate injection)

Lemtrada^® (alemtuzumab)

Mavenclad^® (cladribine)

Mayzent^® (siponimod)

Novantrone^® (mitoxantrone)

Ocrevus^TM (ocrelizumab)

Rebif^® (interferon beta-1a)

Steroid treatments

TYSABRI^® (natalizumab)

Other

No previous treatment

**How do you rate your satisfaction with your current treatment?

**Have you ever treated your relapsing forms of MS?

Yes

No

*When did you stop treating your relapsing forms of MS?

*When was the person you know diagnosed with relapsing forms of MS?

**Is the person you know currently treating his/her relapsing forms of MS?

Yes

No

I don’t know

**What is the person you know currently taking to treat his/her relapsing forms of MS?

*What has the person you know previously taken to treat his/her relapsing forms of MS? Check all that apply:
--Please see below for Important Safety Information (ISI) and full Prescribing Information (PI) for Biogen products, including Boxed Warning and Medication Guide for TYSBRI® (natalizumab), Medication Guides for AVONEX® (interferon beta-1a) and PLEGRIDY® (peginterferon beta-1a), and Patient Information fot TECFIDERA® (dimethyl fumarate) and VUMERITY™ (diroximel fumarate). The following are trademarks of the respectives companies listed: Aubagio®-Genzyme Corporation; Betaseron®-Bayer; Copaxone®-Teva Pharmaceutical Industries Ltd.; Extavia®-Novartis AG; Gilenya®-Novartis AG; Glatopa®-Novartis AG; Lemtrada®-Genzyme Corporation; Mavenclad®-EMD Serono Inc; Mayzent®-Novartis AG; Novantrone®-EMD Serono Inc; Ocrevus™-Genentech USA, Inc.; Rebif®-EMD Serono, Inc.

Aubagio^® (teriflunomide)

Betaseron^® (interferon beta-1b)

Copaxone^® (glatiramer acetate injection)

Extavia^® (interferon beta-1b)

Gilenya^® (fingolimod)

Glatopa^® (glatiramer acetate injection)

Lemtrada^® (alemtuzumab)

Mavenclad^® (cladribine)

Mayzent^® (siponimod)

Novantrone^® (mitoxantrone)

Ocrevus^™ (ocrelizumab)

Rebif^® (interferon beta-1a)

Steroid treatments

TYSABRI^® (natalizumab)

Other

No previous treatment

**Has the person you know ever treated his/her relapsing forms of MS?

Yes

No

I don’t know

*When did the person you know with relapsing MS stop treating his/her relapsing MS?

I would like to have a free information kit—full of information about TYSABRI—mailed to my home.

*I agree to the statement below and have read and understand the Legal Disclaimer and Privacy Policy.

I authorize Biogen, and companies working with Biogen, to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by Biogen to help develop new products, services, and programs. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Biogen. Note that Biogen will not sell or transfer your personal data to any unrelated third party for marketing purposes without your express permission. I understand that I may revoke this authorization and choose not to receive information from Biogen by clicking the “unsubscribe” link at the bottom of this page or through a link provided in the emails I receive from Biogen.

What is TYSABRI?

TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important to discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk.

It is not known if TYSABRI is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TYSABRI?

TYSABRI increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (PML)—that usually leads to death or severe disability.

There is no known treatment, prevention, or cure for PML
You should not take certain medicines that weaken your immune system at the same time you are taking TYSABRI. Even if you use TYSABRI alone to treat your MS, you can still get PML
Your risk of getting PML is higher if you:
- have been infected by the John Cunningham Virus (JCV). JCV is a common virus that can cause PML in people who have weakened immune systems, such as people taking TYSABRI. Before or while you receive TYSABRI, your doctor may do a blood test to check if you have been infected by JCV
- have received TYSABRI for a long time, especially for longer than 2 years
- have received certain medicines that can weaken your immune system before you start receiving TYSABRI
Your risk of getting PML is greatest if you have all 3 risk factors listed above. There may be other risk factors that have not yet been identified
Patients who are anti-JCV antibody negative are still at risk for the development of PML due to the potential for a new JCV infection or a false negative test result. Therefore, patients with a negative test result should be retested periodically
While you receive TYSABRI, and for 6 months after you stop receiving TYSABRI, it is important that you call your doctor right away if you have any new or worsening medical problems (such as problems with your thinking, eyesight, balance, or strength; weakness on 1 side of your body; and using your arms and legs) that have lasted several days. Tell all of your doctors that you are getting treatment with TYSABRI
Because of your risk of getting PML while you receive TYSABRI, TYSABRI is available only through a restricted distribution program called the TOUCH^® Prescribing Program

Who should not receive TYSABRI?

Do not receive TYSABRI if you have PML or are allergic to natalizumab or any of the ingredients in TYSABRI.

What should I tell my doctor before receiving each dose of TYSABRI?

Before receiving TYSABRI, it is important to tell your doctor:

If you have a medical condition that can weaken your immune system, such as HIV infection or AIDS, leukemia or lymphoma, organ transplant, or others, or if you have any new or worsening medical problems that have lasted several days
If you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed. It is not known if TYSABRI can harm your unborn baby or if the TYSABRI that passes into your breast milk can harm your baby
About all of the medicines and supplements you take, especially medicines that can weaken your immune system. If you are not sure, ask your doctor

What are the possible side effects of TYSABRI?

TYSABRI can cause serious side effects. If you have any of the symptoms listed below, call your doctor right away:

Herpes infections. Increased risk of infection of the brain or the covering of your brain and spinal cord (encephalitis or meningitis) caused by herpes viruses that may lead to death. Symptoms include sudden fever, severe headache, or confusion. Infection of the eye caused by herpes viruses leading to blindness in some patients has occurred. Call your doctor if you have changes in vision, redness, or eye pain
Liver damage. Symptoms include yellowing of the skin and eyes (jaundice), unusual darkening of the urine, nausea, feeling tired or weak, or vomiting
Allergic reactions (e.g., hives, itching, trouble breathing, chest pain, dizziness, wheezing, chills, rash, nausea, flushing of skin, low blood pressure), including serious allergic reactions (e.g., anaphylaxis). Serious allergic reactions usually happen within 2 hours of the start of the infusion, but they can happen any time after receiving TYSABRI
Weakened immune system. TYSABRI may increase your risk of getting an unusual or serious infection
Low platelet counts. TYSABRI may cause the number of platelets in your blood to be reduced. Symptoms include easy bruising, small scattered red spots on your skin that are red, pink or purple, heavier menstrual periods than are normal, bleeding from your gums or nose that is new or takes longer than usual to stop, bleeding from a cut that is hard to stop

The most common side effects of TYSABRI are:

Headache, urinary tract infection, lung infection, pain in your arms and legs, vaginitis, stomach-area pain, feeling tired, joint pain, depression, diarrhea, rash, nose and throat infections, and nausea. If you experience any side effect that bothers you or does not go away, tell your doctor

These are not all of the possible side effects of TYSABRI. For more information, ask your doctor. To report side effects to FDA, please call 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed Warning and Medication Guide.

This information does not take the place of talking with your doctor about your medical condition or your treatment.

IMPORTANT SAFETY INFORMATION AND INDICATION

EXPAND

What is TYSABRI?

TYSABRI is a prescription medicine used to treat relapsing...

IMPORTANT SAFETY INFORMATION

TYSABRI increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy...

IMPORTANT SAFETY INFORMATION AND INDICATION

EXPAND

COLLAPSE

IMPORTANT SAFETY INFORMATION

TYSABRI increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (PML)—that usually leads to death or severe disability...TYSABRI increases your risk of getting a rare brain infection—called...TYSABRI increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (PML)—that usually leads to death or severe disability...

What is TYSABRI?

TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome...TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS)...TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS)...

IMPORTANT SAFETY INFORMATION AND INDICATION

COLLAPSE

What is TYSABRI?

TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and continuing treatment with TYSABRI, it is important to discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk.

It is not known if TYSABRI is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TYSABRI?

TYSABRI increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (PML)—that usually leads to death or severe disability.

There is no known treatment, prevention, or cure for PML
You should not take certain medicines that weaken your immune system at the same time you are taking TYSABRI. Even if you use TYSABRI alone to treat your MS, you can still get PML
Your risk of getting PML is higher if you:
- have been infected by the John Cunningham Virus (JCV). JCV is a common virus that can cause PML in people who have weakened immune systems, such as people taking TYSABRI. Before or while you receive TYSABRI, your doctor may do a blood test to check if you have been infected by JCV
- have received TYSABRI for a long time, especially for longer than 2 years
- have received certain medicines that can weaken your immune system before you start receiving TYSABRI
Your risk of getting PML is greatest if you have all 3 risk factors listed above. There may be other risk factors that have not yet been identified
Patients who are anti-JCV antibody negative are still at risk for the development of PML due to the potential for a new JCV infection or a false negative test result. Therefore, patients with a negative test result should be retested periodically
While you receive TYSABRI, and for 6 months after you stop receiving TYSABRI, it is important that you call your doctor right away if you have any new or worsening medical problems (such as problems with your thinking, eyesight, balance, or strength; weakness on 1 side of your body; and using your arms and legs) that have lasted several days. Tell all of your doctors that you are getting treatment with TYSABRI
Because of your risk of getting PML while you receive TYSABRI, TYSABRI is available only through a restricted distribution program called the TOUCH^® Prescribing Program

Who should not receive TYSABRI?

Do not receive TYSABRI if you have PML or are allergic to natalizumab or any of the ingredients in TYSABRI.

What should I tell my doctor before receiving each dose of TYSABRI?

Before receiving TYSABRI, it is important to tell your doctor:

If you have a medical condition that can weaken your immune system, such as HIV infection or AIDS, leukemia or lymphoma, organ transplant, or others, or if you have any new or worsening medical problems that have lasted several days
If you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed. It is not known if TYSABRI can harm your unborn baby or if the TYSABRI that passes into your breast milk can harm your baby
About all of the medicines and supplements you take, especially medicines that can weaken your immune system. If you are not sure, ask your doctor

What are the possible side effects of TYSABRI?

TYSABRI can cause serious side effects. If you have any of the symptoms listed below, call your doctor right away:

Herpes infections. Increased risk of infection of the brain or the covering of your brain and spinal cord (encephalitis or meningitis) caused by herpes viruses that may lead to death. Symptoms include sudden fever, severe headache, or confusion. Infection of the eye caused by herpes viruses leading to blindness in some patients has occurred. Call your doctor if you have changes in vision, redness, or eye pain
Liver damage. Symptoms include yellowing of the skin and eyes (jaundice), unusual darkening of the urine, nausea, feeling tired or weak, or vomiting
Allergic reactions (e.g., hives, itching, trouble breathing, chest pain, dizziness, wheezing, chills, rash, nausea, flushing of skin, low blood pressure), including serious allergic reactions (e.g., anaphylaxis). Serious allergic reactions usually happen within 2 hours of the start of the infusion, but they can happen any time after receiving TYSABRI
Weakened immune system. TYSABRI may increase your risk of getting an unusual or serious infection
Low platelet counts. TYSABRI may cause the number of platelets in your blood to be reduced. Symptoms include easy bruising, small scattered red spots on your skin that are red, pink or purple, heavier menstrual periods than are normal, bleeding from your gums or nose that is new or takes longer than usual to stop, bleeding from a cut that is hard to stop

The most common side effects of TYSABRI are:

Headache, urinary tract infection, lung infection, pain in your arms and legs, vaginitis, stomach-area pain, feeling tired, joint pain, depression, diarrhea, rash, nose and throat infections, and nausea. If you experience any side effect that bothers you or does not go away, tell your doctor

These are not all of the possible side effects of TYSABRI. For more information, ask your doctor. To report side effects to FDA, please call 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed Warning and Medication Guide.

This information does not take the place of talking with your doctor about your medical condition or your treatment.

Stay Connected

Sign up with us to receive the latest news, support information and upcoming events.

Please enter a valid email address.

About TYSABRI

Why TYSABRI? TYSABRI safety Long-term study Taking TYSABRI How TYSABRI may work

Starting TYSABRI

Talking to your doctor The TOUCH Program Find an infusion site Infusion reminders

What is relapsing MS?

Learn about RMS RMS glossary

Personal stories

Fighter blog Fighter videos

Support & events

Biogen Support Services Support Coordinators Nurse Educators Financial & insurance assistance TYSABRI events Care partner resources

Important Safety Information
Medication Guide
Prescribing Information
For Healthcare Professionals

Important Safety Information
Medication Guide
Prescribing Information
For Healthcare Professionals

Terms of Use
Privacy Policy
Contact Us
Unsubscribe

Terms of Use
Privacy Policy
Contact Us
Unsubscribe

© 2021 Biogen. All Rights Reserved. TYS-US-2303v8
TYS-US-2303v8

This site is intended for residents 18 years or older of the United States, Puerto Rico, and US Territories.

All trademarks are the property of their respective owners.